Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | |
Tipo de documento: | preprint |
Idioma: | eng |
Título da fonte: | SciELO Preprints |
Texto Completo: | https://preprints.scielo.org/index.php/scielo/preprint/view/518 |
Resumo: | Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality. |
id |
SCI-1_d836b0cd76dd67f9809b62b2ab09af78 |
---|---|
oai_identifier_str |
oai:ops.preprints.scielo.org:preprint/518 |
network_acronym_str |
SCI-1 |
network_name_str |
SciELO Preprints |
repository_id_str |
|
spelling |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?COVID-19coronavirusanticoagulantsthrombosispreventionhospital mortalityCOVID-19coronavirusanticoagulantsthrombosispreventionhospital mortalityMany patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-18info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/518enghttps://preprints.scielo.org/index.php/scielo/article/view/518/654Copyright (c) 2020 Paulo Eduardo Ocke Reis, Marcos Cesar Braga Limahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessReis, Paulo Eduardo OckeLima, Marcos Cesar Bragareponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-18T19:21:23Zoai:ops.preprints.scielo.org:preprint/518Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-18T19:21:23SciELO Preprints - SciELOfalse |
dc.title.none.fl_str_mv |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
title |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
spellingShingle |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? Reis, Paulo Eduardo Ocke COVID-19 coronavirus anticoagulants thrombosis prevention hospital mortality COVID-19 coronavirus anticoagulants thrombosis prevention hospital mortality |
title_short |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
title_full |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
title_fullStr |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
title_full_unstemmed |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
title_sort |
Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications? |
author |
Reis, Paulo Eduardo Ocke |
author_facet |
Reis, Paulo Eduardo Ocke Lima, Marcos Cesar Braga |
author_role |
author |
author2 |
Lima, Marcos Cesar Braga |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Reis, Paulo Eduardo Ocke Lima, Marcos Cesar Braga |
dc.subject.por.fl_str_mv |
COVID-19 coronavirus anticoagulants thrombosis prevention hospital mortality COVID-19 coronavirus anticoagulants thrombosis prevention hospital mortality |
topic |
COVID-19 coronavirus anticoagulants thrombosis prevention hospital mortality COVID-19 coronavirus anticoagulants thrombosis prevention hospital mortality |
description |
Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA2DS2-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-05-18 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/preprint info:eu-repo/semantics/publishedVersion |
format |
preprint |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/preprint/view/518 |
url |
https://preprints.scielo.org/index.php/scielo/preprint/view/518 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/article/view/518/654 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Paulo Eduardo Ocke Reis, Marcos Cesar Braga Lima https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Paulo Eduardo Ocke Reis, Marcos Cesar Braga Lima https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
dc.source.none.fl_str_mv |
reponame:SciELO Preprints instname:SciELO instacron:SCI |
instname_str |
SciELO |
instacron_str |
SCI |
institution |
SCI |
reponame_str |
SciELO Preprints |
collection |
SciELO Preprints |
repository.name.fl_str_mv |
SciELO Preprints - SciELO |
repository.mail.fl_str_mv |
scielo.submission@scielo.org |
_version_ |
1797047817875750912 |